IBTK and B-cell chronic lymphocytic leukemia: The results of inhibition of SPA by BTKi are in accordance with previous observations of SPA inhibition in blood by pre-incubating blood with various irreversible BTKi in vitro or by oral intake of ibrutinib ex vivo, either by CLL patients or by healthy volunteers [18].